Rapid Response, No Ultracold: China Sees Global Opening For Vaccine Supplies
Lower Costs Another Benefit?
Executive Summary
SinoVac’s rapid antibody response, CanSino’s easier logistics requirements - plus cost advantages - make Chinese developers optimistic about supplying the world with COVID vaccines.
You may also be interested in...
China Poised To Conditionally Approve First COVID Vaccine
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.
Pfizer And Moderna’s Cold War On COVID Gets Competitive
Ahead of anticipated emergency use approvals, Pfizer and Moderna are promoting the benefits of their rival mRNA vaccines.
Coronavirus Vaccines As A Public Good: How Reasonable Is Reasonable?
During a recent press briefing, health officials in China disclosed the country is poised to reach an annual production capacity of 610 million doses for coronavirus vaccines. But they said prices must be based on manufacturing costs and not driven by supply and demand.
Need a specific report? 1000+ reports available
Buy Reports